Iovance Biotherapeutics, Inc. IOVA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers SquibbBMY

$207M+6.7%

ImmunityBio, Inc.IBRX

$7.63M+2.2%

Cullinan Therapeutics, Inc.CGEM

$666K-52.2%

Artiva Biotherapeutics, Inc.ARTV

$3.3M-6.7%

IncyteINCY

$5.59M-9.5%

Kyverna Therapeutics, Inc.KYTX

$1.76M-42.7%

FAQ

What is Iovance Biotherapeutics, Inc.'s operating lease liabilities (current)?

Iovance Biotherapeutics, Inc. (IOVA) reported operating lease liabilities (current) of $2.67M in Q2 2026.

How has Iovance Biotherapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?

Iovance Biotherapeutics, Inc.'s operating lease liabilities (current) decreased by 62.2% year-over-year, from $7.07M to $2.67M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease liabilities (current)?

Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease liabilities (current) has grown at a -8.4% compound annual growth rate (CAGR), from $6.28M to $4.04M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.